1389326-47-9

Upstream product

• 24091-92-7 methyl 2-bromo-2-(4-chlorophenyl)acetate 
• 2942-40-7 nitro-4 indazole 
• 1878-66-6 4-chlorophenylacetic Acid 

Downstream Products

• 1389324-31-5 methyl 2-(4-chlorophenyl)-2-{4-[(methylsulfonyl)amino]-1H-indazol-1-yl}butanoate 
• 1389326-83-3 tert-butyl 1-(2-(4-chlorophenyl)-4,4,4-trifluoro-1-oxobutan-2-yl)-1H-indazol-4-ylcarbamate 
• 1389326-82-2 tert-butyl 1-(2-(4-chlorophenyl)-4,4,4-trifluoro-1-hydroxybutan-2-yl)-1H-indazol-4-ylcarbamate 
• 1389326-81-1 methyl 2-(4-(tert-butoxycarbonylamino)-1H-indazol-1-yl)-2-(4-chlorophenyl)-4,4,4-trifluorobutanoate 
• 1389325-79-4 N-(1-(1-(4-chlorophenyl)-1-(3-cyano-1,2,4-oxadiazol-5-yl)propyl)-1H-indazol-4-yl)methanesulfonamide 
• 1389325-78-3 5-(1-(4-chlorophenyl)-1-(4-(methylsulfonamido)-1H-indazol-1-yl)propyl)-1,2,4-oxadiazole-3-carboxamide 
• 1389326-80-0 ethyl 5-(1-(4-chlorophenyl)-1-(4-(methylsulfonamido)-1H-indazol-1-yl)propyl)-1,2,4-oxadiazole-3-carboxylate 
• 1389326-79-7 ethyl 5-(1-(4-amino-1H-indazol-1-yl)-1-(4-chlorophenyl)propyl)-1,2,4-oxadiazole-3-carboxylate 
• 1389326-78-6 ethyl 5-(1-(4-((tert-butoxycarbonyl)amino)-1H-indazol-1-yl)-1-(4-chlorophenyl)propyl)-1,2,4-oxadiazole-3-carboxylate 
• 1389326-77-5 ethyl 2-amino-2-(((2-(4-((tert-butoxycarbonyl)amino)-1H-indazol-1-yl)-2-(4-chlorophenyl)butanoyl)oxy)imino)acetate 
• 1389326-76-4 2-(4-((tert-butoxycarbonyl)amino)-1H-indazol-1-yl)-2-(4-chlorophenyl)butanoic acid 
• 1389325-34-1 N-(1-(1-(4-chlorophenyl)-1-(2-cyanocyclopropyl)propyl)-1H-indazol-4-yl)methanesulfonamide 
• 1389326-56-0 N-(1-(1-(4-chlorophenyl)-1-(2-cyanocyclopropyl)propyl)-1H-indazol-4-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide 
• 1389326-55-9 (E)-N-(1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1H-indazol-4-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide 

Relevant academic research and scientific papers

Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization

The derivatization of pharmaceuticals is a core activity in the discovery and development of new medicines. Late-stage functionalization via modern C–H functionalization chemistry has emerged as a powerful technique with which to diversify advanced pharma

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl